A randomised phase II study of two dose schedules of PI-88 in combination with docetaxel in patients with androgen-independent prostate cancer.

Trial Profile

A randomised phase II study of two dose schedules of PI-88 in combination with docetaxel in patients with androgen-independent prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Muparfostat (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ProPIT
  • Sponsors Progen Pharmaceuticals Limited
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top